Trulicity Cost in Iowa 2026: Prices, Medicaid, Insurance, and Legal Alternatives

What Does Trulicity Actually Cost in Iowa in 2026?

The retail cash price for Trulicity in Iowa sits at $931 per month in 2026, matching Eli Lilly's national list price. That figure applies to all four pen strengths: 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg. No Iowa-specific state pricing law currently caps GLP-1 agonist list prices, so what you pay out of pocket depends almost entirely on your insurance tier and any manufacturer assistance you qualify for.

Retail pharmacies across Iowa, including Hy-Vee Pharmacy, Walgreens, CVS, and independent chains, all price at or near that $931 ceiling without a discount card or insurance. GoodRx and similar coupon aggregators sometimes reduce the cash price by 10 to 15 percent at selected locations, but savings are inconsistent and can disappear at refill. Confirm any posted price directly with the dispensing pharmacist before you count on it.

Dulaglutide belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist class. It works by stimulating glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying. The FDA approved it in September 2014 for adults with type 2 diabetes [1]. A 2019 label update added cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease [2]. The REWIND trial (N=9,901, median follow-up 5.4 years) showed that dulaglutide 1.5 mg once weekly reduced the composite of major adverse cardiovascular events (MACE) by 12 percent relative to placebo (hazard ratio 0.88 to 95% CI 0.79 to 0.99, P=0.026) [3]. That cardiovascular outcome data underpins much of the clinical argument for prioritizing GLP-1 agents over older diabetes drugs in high-risk patients.

GLP-1 receptor agonists as a class are associated with 0.5 to 1.5 percent reductions in HbA1c at standard doses [4]. The American Diabetes Association 2024 Standards of Care list dulaglutide among preferred agents for patients with type 2 diabetes who have atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease [5].

Does Iowa Medicaid Cover Trulicity?

Iowa Medicaid does not cover Trulicity (dulaglutide) for type 2 diabetes as of 2026. The Iowa Medicaid preferred drug list (PDL) excludes branded dulaglutide. This affects roughly 900,000 Iowans currently enrolled in Iowa Medicaid, including those in the Iowa Health and Wellness Plan [6].

Some GLP-1 agents do appear on Iowa Medicaid's PDL in limited circumstances, primarily when prescribed for type 2 diabetes with prior authorization and documented step-therapy failure on metformin plus a sulfonylurea. Even then, coverage tends to go to lower-cost generics or preferred branded agents, not Trulicity. A generic dulaglutide does not yet exist in the United States market; the FDA has not approved any dulaglutide biosimilar as of early 2025 [7].

Iowa Medicaid members who receive a Trulicity prescription face full cash-pay pricing unless their prescriber obtains a successful prior authorization exception, which is rarely granted for this drug under current PDL policy. If you are on Iowa Medicaid and your provider recommends a GLP-1 agonist, ask whether a preferred alternative like semaglutide (if listed) or a formulary-covered SGLT-2 inhibitor could achieve similar cardiovascular or glycemic outcomes. The ADA 2024 guidelines note that for patients where cost is a barrier, "metformin combined with a formulary-covered SGLT-2 inhibitor or GLP-1 RA should be prioritized" [5].

Medicare Part D coverage for Trulicity requires a separate coverage determination. Most Medicare Part D plans include dulaglutide on Tier 3 or Tier 4, with monthly cost sharing ranging from $60 to $200 depending on your plan's formulary. The Lilly savings card discussed below does not apply to Medicare Part D enrollees.

Which Private Insurance Plans Cover Trulicity in Iowa?

Coverage among Iowa commercial insurers varies by plan year and formulary tier. Most major Iowa carriers, including Wellmark Blue Cross Blue Shield of Iowa, Medica, and UnitedHealthcare Iowa marketplace plans, include dulaglutide on their formularies, though often at Tier 3 or Tier 4, which means higher cost sharing.

A Tier 3 specialty drug copay in Iowa commercial plans typically runs between $60 and $150 per month after deductible. Plans with a high-deductible structure may require you to pay the full list price until you meet your deductible, which can be $1,500 to $3,000 or more depending on the plan. The Kaiser Family Foundation analysis of Iowa marketplace plans found that average individual deductibles for silver-tier plans exceeded $3 to 800 in 2024 [8].

Prior authorization is standard. Insurers typically require documented HbA1c above 7.5 percent on maximum tolerated metformin and at least one additional agent before approving a GLP-1 agonist. Some plans add a body-mass-index threshold, requiring BMI <30 or a weight-related comorbidity if the prescription is written off-label for weight management rather than type 2 diabetes. Trulicity is not FDA-approved for obesity or weight loss; semaglutide 2.4 mg (Wegovy) carries that specific indication [9].

To check your specific plan's coverage: call the member services number on your insurance card and ask whether dulaglutide (NDC prefix 00002) is on the current formulary, what tier it sits on, and what step-therapy requirements apply. Get the answer in writing before your provider submits the prior authorization.

How Does the Eli Lilly Trulicity Savings Card Work in Iowa?

The Lilly Trulicity savings card reduces monthly out-of-pocket cost to as low as $25 per month for commercially insured patients who qualify. Iowa residents with private employer-sponsored insurance or marketplace insurance are generally eligible. The card does not work for patients covered by any federal or state government program, including Iowa Medicaid, Medicare Part D, CHIP, TRICARE, or the VA [10].

Eligible patients enroll at LillyInsulin.com or through a HealthRX-linked enrollment portal, then present the card at any participating Iowa pharmacy. The card covers the gap between your insurance's cost sharing and the $25 cap, up to a defined maximum benefit per year (Lilly sets this limit; verify the current cap at enrollment). If your insurance denies coverage entirely and you are paying full cash price, the savings card may not apply or may offer only a partial reduction. Confirm with the Lilly patient services line at 1-800-545-5979.

Lilly also offers the Lilly Insulin Value Program for patients with no insurance or who are underinsured, though this program is primarily structured around insulin products rather than GLP-1 agents. For uninsured Iowans who cannot afford the $931 list price, the Lilly Cares Foundation patient assistance program may supply Trulicity at no cost, subject to income qualification (generally household income at or below 400 percent of the federal poverty level) [10].

Is Compounded Dulaglutide Legal in Iowa?

Compounded dulaglutide is legal in Iowa when dispensed by a state-licensed 503A compounding pharmacy operating under a valid prescription. Iowa's Board of Pharmacy licenses and regulates 503A pharmacies under Iowa Code Chapter 155A and aligns with federal FDCA requirements for compounding [11].

A 503A pharmacy compounds medications for individual patients based on a practitioner's prescription. These pharmacies may compound dulaglutide peptide formulations, and some Iowa-licensed 503As or pharmacies shipping into Iowa do so legally. The cost is typically lower than branded Trulicity, sometimes substantially so, though exact pricing depends on the pharmacy and dose. Patients have reported cash prices ranging from $100 to $300 per month for compounded dulaglutide, though HealthRX does not guarantee any specific price from a third-party pharmacy.

Three things to verify before using a compounded dulaglutide product in Iowa:

1. The pharmacy holds a current Iowa Board of Pharmacy license or is validly licensed in its home state and legally ships into Iowa.
2. Your prescribing provider has issued a patient-specific prescription, not a standing order for a bulk supply.
3. The compound uses pharmaceutical-grade active pharmaceutical ingredient (API), not research-grade peptide purchased outside the pharmaceutical supply chain.

The FDA has not approved any compounded dulaglutide product for safety or efficacy. Compounded drugs bypass the FDA approval process, so potency, sterility, and bioavailability are not guaranteed by a federal review [12]. The FDA's guidance on compounding makes clear that "compounded drugs are not FDA-approved," and the agency has issued warning letters to pharmacies producing GLP-1 compounds that do not meet quality standards [12]. Iowa patients using compounded dulaglutide should obtain it only from a pharmacy their provider has vetted and should report any adverse reactions to MedWatch at fda.gov/safety/medwatch [13].

Can You Get a Trulicity Prescription via Telehealth in Iowa?

Telehealth prescribing of Trulicity is legal in Iowa. Iowa participates in the Interstate Medical Licensure Compact, which allows physicians licensed in other compact states to prescribe to Iowa patients via telehealth without a separate Iowa license [14]. Nurse practitioners and physician assistants may also prescribe dulaglutide under Iowa law, provided they hold appropriate Iowa licensure or a compact authorization.

A valid prescriber-patient relationship must be established before a controlled or non-controlled prescription is issued. For GLP-1 agents in Iowa, this means a clinical encounter, which can be conducted entirely by video or asynchronous messaging under Iowa's current telehealth standards, that documents relevant history, diabetes diagnosis or risk factors, current medications, contraindications (personal or family history of medullary thyroid carcinoma or MEN2 syndrome is an absolute contraindication per the FDA label [2]), and a treatment plan.

HealthRX's Iowa-licensed providers can complete this evaluation and, when clinically appropriate, send a Trulicity prescription electronically to any Iowa pharmacy or to a licensed 503A compounding pharmacy. The average time from intake form completion to prescription transmission through HealthRX is under 24 hours for straightforward cases.

What Are the Cheapest Ways to Get Dulaglutide in Iowa?

Cost reduction strategies, ranked roughly from lowest to highest monthly out-of-pocket:

Lilly patient assistance (uninsured, income-qualifying): $0/month through Lilly Cares Foundation, for patients meeting income thresholds [10].

Compounded dulaglutide via licensed 503A pharmacy: Approximately $100 to $300/month cash pay, no insurance required, legal with a valid prescription in Iowa.

Lilly savings card with commercial insurance: $25/month copay for eligible commercially insured patients [10].

GoodRx or pharmacy discount cards at retail: Variable reductions off the $931 list price, typically 10 to 15 percent. Confirm at time of pickup.

Commercial insurance with formulary coverage: $60 to $150/month at Tier 3, after deductible.

Full cash pay without assistance: $931/month.

The ADA's 2024 guidelines specifically note that cost is a legitimate clinical factor: "When cost is a major issue, consider drugs with proven efficacy and low cost, such as metformin and sulfonylureas" as a bridge while pursuing assistance programs [5]. Iowa providers should document cost as a barrier in the chart note, which strengthens prior authorization appeals.

Dosing, Administration, and Clinical Benchmarks

Trulicity is injected subcutaneously once per week. The starting dose is 0.75 mg, which may be increased to 1.5 mg after four weeks if additional glycemic control is needed. Further escalation to 3 mg and then 4.5 mg is supported by the AWARD-11 trial (N=1,842), which showed that dulaglutide 4.5 mg reduced HbA1c by a mean of 1.87 percent from baseline versus 1.21 percent for 1.5 mg at 36 weeks [15]. Weight loss at 4.5 mg was also greater: 4.7 kg versus 2.7 kg at 36 weeks [15].

The pen is single-use and self-administered. Patients inject into the abdomen, thigh, or upper arm. No mixing or reconstitution is required. Injection site should rotate weekly. Trulicity does not require refrigeration for up to 14 days at room temperature at or below 30 degrees Celsius, which is relevant for Iowa patients during summer months [2].

Common adverse effects include nausea (in up to 21 percent of patients at initiation), diarrhea (up to 12 percent), and vomiting (up to 8 percent) based on AWARD trial data [16]. These effects are dose-dependent and typically resolve within the first four to eight weeks. Starting at 0.75 mg and escalating slowly reduces GI side-effect burden.

The boxed warning on the Trulicity FDA label covers risk of thyroid C-cell tumors observed in rodent studies. The clinical relevance in humans is uncertain, but the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 [2].

Renal dosing adjustment is not required for mild to moderate chronic kidney disease. The REWIND trial included patients with eGFR as low as 15 mL/min/1.73 m2, and subgroup analyses suggested no increased renal risk [3]. The ADA-KDIGO consensus for diabetic kidney disease supports GLP-1 use alongside SGLT-2 inhibitors in patients with CKD and type 2 diabetes [17].

How Trulicity Compares to Other GLP-1 Options Available in Iowa

Dulaglutide is one of several GLP-1 receptor agonists available by prescription in Iowa in 2026. Understanding the comparative clinical and cost profile helps providers and patients make informed decisions.

Semaglutide 0.5 mg and 1 mg (Ozempic) is a weekly injectable approved for type 2 diabetes. The SUSTAIN-6 trial (N=3,297) showed semaglutide 0.5 mg and 1 mg reduced MACE by 26 percent relative to placebo (HR 0.74 to 95% CI 0.58 to 0.95, P<0.001 for non-inferiority) [18]. Ozempic's list price is comparable to Trulicity at approximately $935 per month. Semaglutide 2.4 mg (Wegovy) is the weight-management formulation, with the STEP-1 trial (N=1,961) demonstrating 14.9 percent mean body weight reduction at 68 weeks versus 2.4 percent with placebo [9].

Liraglutide (Victoza) is a daily injectable. LEADER trial data (N=9,340) showed a 13 percent relative risk reduction in MACE at a median 3.8 years (HR 0.87 to 95% CI 0.78 to 0.97, P<0.001 for non-inferiority) [19]. Its daily dosing frequency is a disadvantage for adherence compared to Trulicity's once-weekly schedule. LEADER was a landmark outcomes trial for this class [19].

Tirzepatide (Mounjaro) is a dual GIP/GLP-1 agonist approved for type 2 diabetes. The SURPASS-2 trial (N=1,879) showed HbA1c reductions of 2.01 to 2.30 percent across dose groups versus 1.86 percent for semaglutide 1 mg at 40 weeks [20]. Its list price is approximately $1,060/month, above Trulicity. The SURMOUNT-1 trial (N=2,539) showed up to 22.5 percent mean weight loss at 72 weeks at the 15 mg dose [21].

For Iowa patients whose primary concern is cost and who have type 2 diabetes without a compelling cardiovascular indication for a specific agent, compounded dulaglutide or a formulary-preferred GLP-1 via insurance may offer the best access. For patients with established ASCVD, the REWIND and LEADER trial data both support using an agent with proven MACE reduction, and Iowa providers should weigh formulary access against outcome evidence when selecting among options.

Iowa-Specific Access Considerations in 2026

Iowa has 99 counties, and pharmacy access in rural areas differs from Des Moines, Cedar Rapids, Iowa City, or Sioux City. Patients in counties without a 24-hour retail pharmacy may benefit from mail-order dispensing, which most Iowa commercial plans cover at 90-day supplies for maintenance medications. A 90-day Trulicity supply under a savings card or insurance plan can reduce dispensing fees and minimize travel for rural residents.

Iowa's telehealth parity law (Iowa Code 514C.34) requires commercial insurance plans to reimburse telehealth services at parity with in-person services for covered benefits [22]. This means an Iowa commercially insured patient can use a telehealth visit to initiate or manage a Trulicity prescription at the same cost sharing as an office visit. Iowa Medicaid's telehealth coverage policies are more restrictive; confirm eligibility before scheduling.

Iowa pharmacists can legally provide collaborative drug therapy management (CDTM) services under a collaborative practice agreement with a physician [23]. This means your Iowa pharmacist, under an active CDTM agreement, may be able to adjust your Trulicity dose or manage refills without an additional physician visit, reducing appointment burden for stable patients.

Monitoring Recommendations for Iowa Patients on Dulaglutide

The ADA 2024 Standards of Care recommend HbA1c testing every three months until at-goal, then every six months for stable patients [5]. Iowa patients starting Trulicity should expect a baseline HbA1c, fasting glucose, renal function panel (BMP or CMP), and lipid panel. Patients with a history of pancreatitis warrant careful risk-benefit discussion; the FDA label lists pancreatitis as a potential adverse effect requiring discontinuation if confirmed [2].

Thyroid monitoring: routine serum calcitonin or thyroid ultrasound is not recommended by current guidelines solely because of GLP-1 use, but patients should be counseled to report neck masses, dysphagia, or hoarseness immediately [2]. The Endocrine Society's clinical practice guideline on type 2 diabetes management notes that "GLP-1 receptor agonists do not require routine calcitonin screening in the absence of symptoms" [24].

Weight and blood pressure should be assessed at each visit. In REWIND, dulaglutide produced a mean weight reduction of 1.5 kg and a systolic blood pressure reduction of approximately 1.7 mmHg versus placebo at 5.4 years [3].

Hypoglycemia risk is low when dulaglutide is used as monotherapy or combined with metformin. Risk increases significantly when combined with insulin or sulfonylureas; sulfonylurea dose reduction by 50 percent at initiation is commonly recommended [5].